hotspot -WSS

hotspot

author：explore 2025-10-03 00:41:02 - browse：2

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Asbestos, a deadly carcinogen, banned by EPA

hotspot

WSS

U.K. researchers warn about biases in medical devices, algorithms

Asbestos, a deadly carcinogen, banned by EPA

What's changing in Medicare's open enrollment this year?

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Colonoscopy prep: Liquid

Akero's treatment for NASH falls short in cirrhosis study

focus

hotspot

Gilead needs Arcellx more than ever

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Virtual Event: March of the Biosimilars

The cancer drug shortage isn’t new — and neither are the solutions

SCOTUS questions limit to govt efforts to fight misinformation

George Santos makes 1st court appearance after pleading not guilty to 13 counts

A revolution in caring for preterm infants

Psychedelics group wrestles with new pharma identity

Argenx readies a blockbuster opportunity with drug for autoimmune disease

BioMarin wins approval for gene therapy to treat hemophilia A

UnitedHealth increases loan offers after Change Healthcare outage

leisure time

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Positive childhood experiences can help future health

Gene editing the human germline: What are the risks?

Peter Marks talks Operation Warp Speed for Rare Diseases

Neuroscience’s long legacy of racism

Bernie Sanders bashes nonprofit hospitals over their tax breaks

hotspot

leisure time

hotspot

focus